CRYOPORT, INC. Buildings and Improvements, Gross
CRYOPORT, INC. (CYRX) had Buildings and Improvements, Gross of $6.65 million as of 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:BuildingsAndImprovementsGross · last filed 2024-03-13
- 2023-12-31: Buildings and Improvements, Gross $6.65M.
- 2022-12-31: Buildings and Improvements, Gross $4.47M.
- 2021-12-31: Buildings and Improvements, Gross $5.81M.
- 2020-12-31: Buildings and Improvements, Gross $5.36M.
| Period end | Buildings and Improvements, Gross |
|---|---|
| 2023-12-31 | $6.65M 10-K · filed 2024-03-13 |
| 2022-12-31 | $4.47M 10-K · filed 2024-03-13 |
| 2021-12-31 | $5.81M 10-K · filed 2023-02-28 |
| 2020-12-31 | $5.36M 10-K · filed 2022-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |